MARK3

Across TCGA pan-cancer cohorts, MARK3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MARK3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MARK3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MARK3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where MARK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.915	0.588	.005	14	view →
LUAD	DFS	Median	II,III,IV	0.898	0.228	.002	12	view →
CCRCC	DFS	Tertile	III,IV	0.759	0.343	.004	11	view →
PDAC	OS	Median	All	0.272	0.562	.001	11	view →
UCEC	OS	Median	III,IV	0.904	0.333	.031	4	view →
GBM	DFS	Tertile	All	0.854	0.685	.041	1	view →
HNSC	DFS	Median	II,III,IV	0.984	0.907	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MARK3–LSCC (OS)

Open the LSCC breakdown →